- Home
- SLDP vs MREO Comparison
SLDP vs MREO Comparison
Compare SLDP & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- MREO
- Stock Information
- Founded
- SLDP 2011
- MREO 2015
- Country
- SLDP United States
- MREO United Kingdom
- Employees
- SLDP N/A
- MREO N/A
- Industry
- SLDP Electrical Products
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- MREO Health Care
- Exchange
- SLDP Nasdaq
- MREO Nasdaq
- Market Cap
- SLDP 446.6M
- MREO 438.8M
- IPO Year
- SLDP N/A
- MREO N/A
- Fundamental
- Price
- SLDP $4.33
- MREO $1.71
- Analyst Decision
- SLDP Buy
- MREO Strong Buy
- Analyst Count
- SLDP 2
- MREO 5
- Target Price
- SLDP $2.50
- MREO $7.40
- AVG Volume (30 Days)
- SLDP 10.3M
- MREO 1.3M
- Earning Date
- SLDP 08-06-2025
- MREO 08-12-2025
- Dividend Yield
- SLDP N/A
- MREO N/A
- EPS Growth
- SLDP N/A
- MREO N/A
- EPS
- SLDP N/A
- MREO N/A
- Revenue
- SLDP $22,667,000.00
- MREO $500,000.00
- Revenue This Year
- SLDP $28.39
- MREO N/A
- Revenue Next Year
- SLDP $38.07
- MREO $55.50
- P/E Ratio
- SLDP N/A
- MREO N/A
- Revenue Growth
- SLDP 14.83
- MREO N/A
- 52 Week Low
- SLDP $0.68
- MREO $1.47
- 52 Week High
- SLDP $5.62
- MREO $4.84
- Technical
- Relative Strength Index (RSI)
- SLDP 53.08
- MREO 45.41
- Support Level
- SLDP $3.87
- MREO $1.64
- Resistance Level
- SLDP $5.01
- MREO $1.82
- Average True Range (ATR)
- SLDP 0.51
- MREO 0.09
- MACD
- SLDP -0.07
- MREO 0.03
- Stochastic Oscillator
- SLDP 26.29
- MREO 68.57
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization strategy is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).